The injection, which is made in partnership with Exela Pharma Sciences, will be available to Premier’s member providers. It is the only FDA-approved version of the drug.
Supplies of cysteine hydrochloride are imported from Canada under FDA rules that allow drugs in shortage to be brought in from abroad if no domestic supplies are available.
“This partnership is a game changer for us,” Terry Webb, vice president of pharmacy services at Roselle, Calif.-based Adventist Health, said in a news release. “Having a safer, FDA-approved and domestic supply of cysteine hydrochloride will greatly benefit the newborn patients we serve.”
More articles on supply chain:
Blood shortage spurs rationing, threatens patient care in Southern hospitals
How 2 health systems are moving the needle on costs & outcomes with an optimized supply chain
FDA recalls 3 blood test analyzers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.